세계의 파국적 항인지질 항체 증후군 시장 : 규모, 점유율, 동향 분석 보고서 - 치료별, 최종 용도별, 지역별, 부문별 예측(2024-2030년)

Catastrophic Antiphospholipid Syndrome Market Growth & Trends:

The global catastrophic antiphospholipid syndrome market size is anticipated to reach USD 8.99 billion by 2030 and is projected to grow at a CAGR of 10.7% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market encompasses various aspects related to the diagnosis, treatment, and management of this rare and life-threatening autoimmune disorder.

The rising demand for effective treatment options is critical in the catastrophic antiphospholipid syndrome (CAPS) market. Patients and healthcare providers are actively seeking innovative therapies that can address the unique challenges posed by CAPS, including its rapid progression and multi-organ involvement. The clinical trials are focused on developing targeted therapies that mitigate the severe thrombotic events associated with the syndrome.

The rising prevalence of autoimmune disorders is anticipated to drive the market growth. Autoimmune disorders involve an abnormal immune response where the body mistakenly attacks its tissues. APS, a type of autoimmune disease, can lead to complications, including digestive issues such as irritable bowel syndrome (IBS). According to Crohn's and Colitis Canada, over 322,600 Canadians were estimated to be living with inflammatory bowel disease (IBD) in 2023, which represents about 0.82% of the total population.

Catastrophic Antiphospholipid Syndrome Market Report Highlights:

• Based on treatment, the intravenous immunoglobulin (IVIG) segment led the market with the largest revenue share of 36.93% in 2023. The efficacy of IVIG is supported by various clinical instances where patients with refractory CAPS showed improvement after receiving this therapy, often in conjunction with other treatments such as anticoagulation and corticosteroids
• Based on end-use, the hospital segment led the market with the largest revenue share of 62.80% in 2023. The increasing prevalence of autoimmune diseases and the growing awareness of CAPS among healthcare providers fuel the demand for hospital-based care, as timely interventions can significantly improve patient outcomes and reduce mortality rates associated with this life-threatening condition

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Treatment
  • 1.2.2. End Use
  • 1.2.3. Regional scope
  • 1.2.4. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Treatment Outlook
  • 2.2.2. End Use Outlook
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Catastrophic Antiphospholipid Syndrome Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. The rising incidence of autoimmune diseases
    • 3.2.1.2. Advancements in diagnostic technologies
    • 3.2.1.3. Increased awareness and education about CAPS
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Limited awareness and understanding of CAPS
    • 3.2.2.2. Challenges in the diagnosis and treatment of CAPS
• 3.3. Catastrophic Antiphospholipid Syndrome Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Catastrophic Antiphospholipid Syndrome Market: Treatments Estimates & Trend Analysis

• 4.1. Global Catastrophic Antiphospholipid Syndrome Market: Treatments Dashboard
• 4.2. Global Catastrophic Antiphospholipid Syndrome Market: Treatments Movement Analysis
• 4.3. Global Catastrophic Antiphospholipid Syndrome Market by Treatments, Revenue
• 4.4. Anticoagulants
  • 4.4.1. Anticoagulants market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Immunosuppressive Therapy
  • 4.5.1. Immunosuppressive Therapy market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Plasma Exchange Therapy (Plasmapheresis)
  • 4.6.1. Plasma Exchange Therapy (Plasmapheresis) market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Intravenous Immunoglobulin (IVIG)
  • 4.7.1. Intravenous Immunoglobulin (IVIG) market estimates and forecasts 2018 to 2030 (USD Million)
• 4.8. Other Treatment
  • 4.8.1. Other treatment market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Catastrophic Antiphospholipid Syndrome Market: End Use Estimates & Trend Analysis

• 5.1. Global Catastrophic Antiphospholipid Syndrome Market: End Use Dashboard
• 5.2. Global Catastrophic Antiphospholipid Syndrome Market: End Use Movement Analysis
• 5.3. Global Catastrophic Antiphospholipid Syndrome Market Estimates and Forecasts, By End Use, Revenue (USD Million)
• 5.4. Hospitals
  • 5.4.1. Hospitals market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Clinics
  • 5.5.1. Clinics market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Other
  • 5.6.1. Other market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Catastrophic Antiphospholipid Syndrome Market: Regional Estimates & Trend Analysis by Treatments, and End Use

• 6.1. Regional Dashboard
• 6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 6.3. North America
  • 6.3.1. U.S.
    • 6.3.1.1. Key country dynamics
    • 6.3.1.2. Regulatory framework/ reimbursement structure
    • 6.3.1.3. Competitive scenario
    • 6.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.3.2. Canada
    • 6.3.2.1. Key country dynamics
    • 6.3.2.2. Regulatory framework/ reimbursement structure
    • 6.3.2.3. Competitive scenario
    • 6.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.3.3. Mexico
    • 6.3.3.1. Key country dynamics
    • 6.3.3.2. Regulatory framework/ reimbursement structure
    • 6.3.3.3. Competitive scenario
    • 6.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 6.4. Europe
  • 6.4.1. UK
    • 6.4.1.1. Key country dynamics
    • 6.4.1.2. Regulatory framework/ reimbursement structure
    • 6.4.1.3. Competitive scenario
    • 6.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.2. Germany
    • 6.4.2.1. Key country dynamics
    • 6.4.2.2. Regulatory framework/ reimbursement structure
    • 6.4.2.3. Competitive scenario
    • 6.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.3. France
    • 6.4.3.1. Key country dynamics
    • 6.4.3.2. Regulatory framework/ reimbursement structure
    • 6.4.3.3. Competitive scenario
    • 6.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.4. Italy
    • 6.4.4.1. Key country dynamics
    • 6.4.4.2. Regulatory framework/ reimbursement structure
    • 6.4.4.3. Competitive scenario
    • 6.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.5. Spain
    • 6.4.5.1. Key country dynamics
    • 6.4.5.2. Regulatory framework/ reimbursement structure
    • 6.4.5.3. Competitive scenario
    • 6.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.6. Norway
    • 6.4.6.1. Key country dynamics
    • 6.4.6.2. Regulatory framework/ reimbursement structure
    • 6.4.6.3. Competitive scenario
    • 6.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.7. Sweden
    • 6.4.7.1. Key country dynamics
    • 6.4.7.2. Regulatory framework/ reimbursement structure
    • 6.4.7.3. Competitive scenario
    • 6.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.8. Denmark
    • 6.4.8.1. Key country dynamics
    • 6.4.8.2. Regulatory framework/ reimbursement structure
    • 6.4.8.3. Competitive scenario
    • 6.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Asia Pacific
  • 6.5.1. Japan
    • 6.5.1.1. Key country dynamics
    • 6.5.1.2. Regulatory framework/ reimbursement structure
    • 6.5.1.3. Competitive scenario
    • 6.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.2. China
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. Regulatory framework/ reimbursement structure
    • 6.5.2.3. Competitive scenario
    • 6.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.3. India
    • 6.5.3.1. Key country dynamics
    • 6.5.3.2. Regulatory framework/ reimbursement structure
    • 6.5.3.3. Competitive scenario
    • 6.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.4. Australia
    • 6.5.4.1. Key country dynamics
    • 6.5.4.2. Regulatory framework/ reimbursement structure
    • 6.5.4.3. Competitive scenario
    • 6.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.5. South Korea
    • 6.5.5.1. Key country dynamics
    • 6.5.5.2. Regulatory framework/ reimbursement structure
    • 6.5.5.3. Competitive scenario
    • 6.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.6. Thailand
    • 6.5.6.1. Key country dynamics
    • 6.5.6.2. Regulatory framework/ reimbursement structure
    • 6.5.6.3. Competitive scenario
    • 6.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Latin America
  • 6.6.1. Brazil
    • 6.6.1.1. Key country dynamics
    • 6.6.1.2. Regulatory framework/ reimbursement structure
    • 6.6.1.3. Competitive scenario
    • 6.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.2. Argentina
    • 6.6.2.1. Key country dynamics
    • 6.6.2.2. Regulatory framework/ reimbursement structure
    • 6.6.2.3. Competitive scenario
    • 6.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 6.7. MEA
  • 6.7.1. South Africa
    • 6.7.1.1. Key country dynamics
    • 6.7.1.2. Regulatory framework/ reimbursement structure
    • 6.7.1.3. Competitive scenario
    • 6.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.2. Saudi Arabia
    • 6.7.2.1. Key country dynamics
    • 6.7.2.2. Regulatory framework/ reimbursement structure
    • 6.7.2.3. Competitive scenario
    • 6.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.3. UAE
    • 6.7.3.1. Key country dynamics
    • 6.7.3.2. Regulatory framework/ reimbursement structure
    • 6.7.3.3. Competitive scenario
    • 6.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.4. Kuwait
    • 6.7.4.1. Key country dynamics
    • 6.7.4.2. Regulatory framework/ reimbursement structure
    • 6.7.4.3. Competitive scenario
    • 6.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Company/Competition Categorization
• 7.2. Vendor Landscape
  • 7.2.1. List of key distributors and channel partners
  • 7.2.2. Key company market share analysis, 2023
  • 7.2.3. Pfizer
    • 7.2.3.1. Company overview
    • 7.2.3.2. Financial performance
    • 7.2.3.3. Product benchmarking
    • 7.2.3.4. Strategic initiatives
  • 7.2.4. Abbott
    • 7.2.4.1. Company overview
    • 7.2.4.2. Financial performance
    • 7.2.4.3. Product benchmarking
    • 7.2.4.4. Strategic initiatives
  • 7.2.5. Bristol-Myers Squibb Company
    • 7.2.5.1. Company overview
    • 7.2.5.2. Financial performance
    • 7.2.5.3. Product benchmarking
    • 7.2.5.4. Strategic initiatives
  • 7.2.6. Eli Lilly and Company
    • 7.2.6.1. Company overview
    • 7.2.6.2. Financial performance
    • 7.2.6.3. Product benchmarking
    • 7.2.6.4. Strategic initiatives
  • 7.2.7. Boehringer Ingelheim International GmbH
    • 7.2.7.1. Company overview
    • 7.2.7.2. Financial performance
    • 7.2.7.3. Product benchmarking
    • 7.2.7.4. Strategic initiatives
  • 7.2.8. Novartis AG
    • 7.2.8.1. Company overview
    • 7.2.8.2. Financial performance
    • 7.2.8.3. Product benchmarking
    • 7.2.8.4. Strategic initiatives
  • 7.2.9. Merck KGaA
    • 7.2.9.1. Company overview
    • 7.2.9.2. Financial performance
    • 7.2.9.3. Product benchmarking
    • 7.2.9.4. Strategic initiatives
  • 7.2.10. AbbVie Inc.
    • 7.2.10.1. Company overview
    • 7.2.10.2. Financial performance
    • 7.2.10.3. Product benchmarking
    • 7.2.10.4. Strategic initiatives
  • 7.2.11. F. Hoffmann-La Roche
    • 7.2.11.1. Company overview
    • 7.2.11.2. Financial performance
    • 7.2.11.3. Product benchmarking
    • 7.2.11.4. Strategic initiatives
  • 7.2.12. Johnson & Johnson Services, Inc.
    • 7.2.12.1. Company overview
    • 7.2.12.2. Financial performance
    • 7.2.12.3. Product benchmarking
    • 7.2.12.4. Strategic initiatives